Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)

10 de noviembre de 2026 actualizado por: Fundació Sant Joan de Déu

The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.

Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.

Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.

Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Estimado)

110

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Marta Ramon Krauel, MD PhD
  • Número de teléfono: 71702 +34 932 804 000
  • Correo electrónico: marta.ramon@sjd.es

Ubicaciones de estudio

      • Santiago de Compostela, España
        • Hospital Clínico Universitario de Santiago
        • Contacto:
    • Barcelona
      • Barcelona, Barcelona, España, 08950
        • Hospital Sant Joan de Déu
        • Contacto:
          • Marta Ramon Krauel, MD PhD
          • Número de teléfono: 71702 +34 932 804 000
          • Correo electrónico: marta.ramon@sjd.es
    • Madrid
      • Madrid, Madrid, España
    • Valencia
      • Valencia, Valencia, España
        • Hospital Universitario y Politécnico La Fe
        • Contacto:
    • Zaragoza
      • Zaragoza, Zaragoza, España
        • Hospital Universitario Miguel Servet
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

3 años a 16 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.

Descripción

Inclusion Criteria:

  • Age between 3 and 16 years.
  • Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
  • Growth hormone treatment approved by the relevant local authorities and institution.
  • Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.

Exclusion Criteria:

- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Weekly Long-Acting Growth Hormone

Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

Otros nombres:
  • Somatrogon
  • NGENLA
Daily Recombinant Human Growth Hormone

Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

Otros nombres:
  • Somatropina
  • Norditropina
  • Omnitropo
  • Genotonorm

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Percentage Total Body Fat
Periodo de tiempo: Baseline and 12 months

Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.

Baseline and 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Lean Body Mass
Periodo de tiempo: Baseline and 12 months

Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.

Baseline and 12 months
Change in body mass index standard deviation score (BMI-SDS)
Periodo de tiempo: Baseline and 12 months

Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in height standard deviation score (SDS)
Periodo de tiempo: Baseline and 12 months

Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in Waist Circumference
Periodo de tiempo: Baseline and 12 months

Change in waist circumference from baseline to 12 months, expressed in centimeters.

Baseline and 12 months
Change in Waist-to-Hip Ratio
Periodo de tiempo: Baseline and 12 months

Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.

Baseline and 12 months
Change in Systolic Blood Pressure
Periodo de tiempo: Baseline and 12 months

Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Diastolic Blood Pressure
Periodo de tiempo: Baseline and 12 months

Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Fasting Glucose Concentration
Periodo de tiempo: Baseline and 12 months

Change in fasting blood glucose concentration from baseline to 12 months.

Baseline and 12 months
Change in Fasting Insulin Concentration
Periodo de tiempo: Baseline and 12 months

Change in fasting blood insulin concentration from baseline to 12 months.

Baseline and 12 months
Change in HOMA-IR
Periodo de tiempo: Baseline and 12 months

Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.

Baseline and 12 months
Change in Total Cholesterol Concentration
Periodo de tiempo: Baseline and 12 months

Change in total cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in LDL Cholesterol Concentration
Periodo de tiempo: Baseline and 12 months

Change in LDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in HDL Cholesterol Concentration
Periodo de tiempo: Baseline and 12 months

Change in HDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in Triglyceride Concentration
Periodo de tiempo: Baseline and 12 months

Change in Triglyceride concentration from baseline to 12 months.

Baseline and 12 months
Change in Change in Carotid Intima-Media Thickness
Periodo de tiempo: Baseline and 12 months

Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.

Baseline and 12 months
Change in Bone Mineral Density Z-Score
Periodo de tiempo: Baseline and 12 months

Change in bone mineral density Z-score measured by DXA from baseline to 12 months.

Baseline and 12 months
Change in Height Standard Deviation Score
Periodo de tiempo: Baseline and 12 months

Change in height standard deviation score (height SDS) from baseline to 12 months.

Baseline and 12 months
Change in Growth Velocity Standard Deviation Score
Periodo de tiempo: Baseline and 12 months

Change in growth velocity standard deviation score from baseline to 12 months.

Baseline and 12 months
Change in Bone Age Minus Chronological Age
Periodo de tiempo: Baseline and 12 months

Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.

Baseline and 12 months
Change in IGF-1 standard deviation score
Periodo de tiempo: Baseline and 12 months

Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.

Baseline and 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de junio de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir